tetano
Editor, Senior Moderator
J Med Virol
. 2023 Aug;95(8):e29032.
doi: 10.1002/jmv.29032. Impaired systemic nucleocapsid antigen clearance in severe COVID-19
Christian Bauer[SUP] 1 [/SUP], Elisabeth Mack[SUP] 2 [/SUP], Véronique Hefter[SUP] 3 [/SUP], Alexandra Fischer[SUP] 3 [/SUP], Kirsten Volland[SUP] 3 [/SUP], Chrysanthi Skevaki[SUP] 4 [/SUP], Andreas Neubauer[SUP] 2 [/SUP], Thomas Gress[SUP] 1 [/SUP], Stephan Becker[SUP] 3 [/SUP], Christian Keller[SUP] 3 [/SUP]
Affiliations
The circulating nucleocapsid (NCP) antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is detectable in coronavirus disease-2019 (COVID-19) patients. To better understand the biology of disease severity, we investigated NCP clearance kinetics in hospitalized COVID-19 patients. Serum NCP was quantified using a commercial NCP-specific enzyme-linked immunoassay in hospitalized COVID-19 patients (n = 63) during their hospital stay. Results were correlated to COVID-19 disease severity, inflammation parameters, antibody response, and results of SARS-CoV-2 PCR from nasopharyngeal swabs. We demonstrate that NCP antigen levels in serum remained elevated in 21/45 (46.7%) samples from patients in intensive care units (ICU) after >8 days postdiagnosis. The proportion of ICU patients with detectable antigenemia declined only gradually from 84.6% to 25.0% over several weeks. This was in contrast to complete NCP clearance in all non-ICU patients after 8 days, and also in contrast to mucosal clearance of the virus as measured by PCR. Antigen clearance was associated with higher IgG against S1 but not NCP. Clearance of NCP antigenemia is delayed in >40% of severely ill COVID-19 patients. Thus, NCP antigenemia detected after 8 days post COVID-19 diagnosis is a characteristic of patients requiring intensive care. Prospective trials should further investigate NCP antigen clearance kinetics as a mechanistic biomarker.
Keywords: COVID-19; ELISA; SARS-CoV-2; biomarker; nucleocapsid antigen.
. 2023 Aug;95(8):e29032.
doi: 10.1002/jmv.29032. Impaired systemic nucleocapsid antigen clearance in severe COVID-19
Christian Bauer[SUP] 1 [/SUP], Elisabeth Mack[SUP] 2 [/SUP], Véronique Hefter[SUP] 3 [/SUP], Alexandra Fischer[SUP] 3 [/SUP], Kirsten Volland[SUP] 3 [/SUP], Chrysanthi Skevaki[SUP] 4 [/SUP], Andreas Neubauer[SUP] 2 [/SUP], Thomas Gress[SUP] 1 [/SUP], Stephan Becker[SUP] 3 [/SUP], Christian Keller[SUP] 3 [/SUP]
Affiliations
- PMID: 37581876
- DOI: 10.1002/jmv.29032
The circulating nucleocapsid (NCP) antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is detectable in coronavirus disease-2019 (COVID-19) patients. To better understand the biology of disease severity, we investigated NCP clearance kinetics in hospitalized COVID-19 patients. Serum NCP was quantified using a commercial NCP-specific enzyme-linked immunoassay in hospitalized COVID-19 patients (n = 63) during their hospital stay. Results were correlated to COVID-19 disease severity, inflammation parameters, antibody response, and results of SARS-CoV-2 PCR from nasopharyngeal swabs. We demonstrate that NCP antigen levels in serum remained elevated in 21/45 (46.7%) samples from patients in intensive care units (ICU) after >8 days postdiagnosis. The proportion of ICU patients with detectable antigenemia declined only gradually from 84.6% to 25.0% over several weeks. This was in contrast to complete NCP clearance in all non-ICU patients after 8 days, and also in contrast to mucosal clearance of the virus as measured by PCR. Antigen clearance was associated with higher IgG against S1 but not NCP. Clearance of NCP antigenemia is delayed in >40% of severely ill COVID-19 patients. Thus, NCP antigenemia detected after 8 days post COVID-19 diagnosis is a characteristic of patients requiring intensive care. Prospective trials should further investigate NCP antigen clearance kinetics as a mechanistic biomarker.
Keywords: COVID-19; ELISA; SARS-CoV-2; biomarker; nucleocapsid antigen.